Once-weekly tirzepatide injection from Eli Lilly, FDA-approved for chronic weight management and obstructive sleep apnea in adults with obesity. Self-pay $299 to $449/month via LillyDirect (checked Sept 20, 2026).
FDA-approved for
Verified on September 20, 2026. Source: Eli Lilly, Zepbound coverage and savings page (zepbound.lilly.com). Prices can change, so confirm the final price before you pay.
As little as $25 with the savings card (maximum $100/month and $1,300/year savings; card expires Dec 31, 2026)
Single-dose pen as low as $499/month with the savings card
Eligible beneficiaries may pay no more than $50/month under the Medicare GLP-1 Bridge (terms apply)
Lowest standard self-pay price per month from each manufacturer’s own pharmacy. Introductory offers and insurance prices are excluded. Medications, doses and approved uses differ, so this is a price reference, not a treatment comparison.
Zepbound is a once-weekly tirzepatide injection from Eli Lilly. It is FDA-approved, with a reduced-calorie diet and increased physical activity, for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity.
Self-pay patients can buy Zepbound single-dose vials or the single-patient-use KwikPen through LillyDirect. The $449 price for 7.5 mg and higher doses requires each refill within 45 days of the previous delivery; otherwise the regular price of $499 (7.5 mg) or $699 (10, 12.5 and 15 mg) applies. Prices were checked on September 20, 2026.